Welcome to HitGen

Capabilities & Services

Enabling Innovative Drug Discovery with Advanced Technologies

  • DEL for
    DEL for
  • DNA Encoded Library Design and Synthesis
    DNA Encoded Library Design and Synthesis
  • DNA Encoded Library Screening
    DNA Encoded Library Screening
  • OpenDEL
    OpenDELTM
  • Nucleic Acid Sequence Design
    Nucleic Acid Sequence Design
  • DEL for
    Monomer and Solid Support Chemistry
  • Nucleic Acid Delivery
    Nucleic Acid Delivery
  • CDMO
    CDMO
  • Protein Degradation
    Protein Degradation
  • FBDD/SBDD
    FBDD/SBDD
  • Chemistry
    Chemistry
  • Biology
    Biology
HitGen Inc. is a rapidly developing biotech company
The discovery and development of novel medicines and agrochemicals
>1.2 Trillion

DNA encoded compounds

>6,000

novel drug/target complex structures for FBDD/SBDD

About Us

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.

For media inquiries: media@hitgen.com 

For investor inquiries: investors@hitgen.com

For business development: bd@hitgen.com


Read More

Collaboration Partners

Latest News

  • 25 April 2025

    Infographic | HitGen FY2024&2025Q1 Report

    Infographic | HitGen FY2024&2025Q1 Report
    + Read More
  • 10 April 2025

    Mission BioCapital Announces 2024 Platinum Ticket Investments and Opening of $4 Million 2025 Platinum Program Contest

    Mission BioCapital (MBC), in partnership with sponsors Eli Lilly and Company (Lilly), Ono Venture Investment (OVI), Alloy Therapeutics, and our newest sponsor, HitGen, announced today that applications are open internationally for the 2025 Platinum Program. MBC's Platinum Program aims to advance high-potential life sciences start-up companies by providing pre-seed funding, global laboratory space, expert mentorship, and discovery services to accelerate their launch and initial development. Early-stage biotechnology innovators from around the globe are invited to apply.
    + Read More
  • 26 December 2024

    2025 Pre-Sale|Nucleic Acid Monomer Off 20%|100+ Special Monomers on the Shelf

    2025 Pre-Sale Nucleic Acid Monomer Off 20% 100+ Special Monomers on the Shelf
    + Read More
Investors

Latest Announcements,
Financial News and Stock Information

Read More

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information